Given the uncertainties associated with valuation of biotech enterprises, valuers can put stronger effort in benchmarking. A solid pool of comparable listed companies and comparable transaction will be highly useful to support valuation assumptions at different clinical trial phase.
With respect to the assignment of goodwill and other asset values, valuations for financial reporting purposes involve the allocation of asset values at the reporting unit level, and the acquired assets can be added to an acquirer’s existing reporting units. Book values of assets and liabilities are often different from their fair values. In allocating the purchase price to these assets and liabilities, we step, or write, them up/down to reflect their fair values.